Abstract:
Atopic dermatitis (AD) commonly identified as eczema. AD is an inflammatory, long-lasting, highly pruritic
reverting disease of the skin. AD is classified by disease of outer skin layer barrier function. AD is progress with
Immunoglobulin E facilitated sensitization to food and environmental allergens. One study stated that more than 59.6%
of teen-agers with AD are at high risk of develop asthma or rhinitis. Interaction between genes and environment increase
the prevalence of AD. AD have three standard stages: infantile, childhood, and adulthood. AD sign and symptoms
diverge extensively. AD can be present that simply affect the hand to where a patient presents with erythroderma. AD
present with erythematous papules, extremely pruritic with serous exudate. Lichenified plaques and papules are
symptoms of long lasting AD. Due to outer skin layer barrier dysfunction bacterial and viral infection risk is increased in
AD patients. This study was directed on 100 patients in which 50 are PolymixinB-bacitrin group and 50 are Dermidoc
group. Patients were selected after seeing inclusion and exclusion criteria and taking written informed consent. Dermidoc
group expressively amended skin symptoms associated with AD comparing to the PolymixinB-bacitrin group. The
Dermidoc cream is effective and well tolerated. The results were analysis using paired sample t-test. The p value is
<0.05. Test group (Dermidoc) were significantly more effective than PolymixinB-bacitrin group.
